[Class I anti-arrhythmia agents and prevention of sudden death following myocardial infarction].
The results of therapeutic trials of Class I antiarrhythmic agents after myocardial infarction are not identical or always compatible with those of the CAST. It is important to determine the reason for this disparity in order to try and identify the patients who should not be given these drugs and those in whom they could be beneficial, providing these benefits are clearly demonstrated. Meta-analyses of controlled therapeutic trials of Class I antiarrhythmics after myocardial infarction have been performed. Depending on the study protocol used, the results of the CAST are compatible or incompatible with those of other trials. A possible reason for this apparent discordance from meta-analysis could be the particularly low cardiac risk in the CAST patients.
Boissel
J P
JP
Unité de pharmacologie clinique, hôpital Neuro-cardiologique, Lyon.
Lièvre
M
M
Rosenberg
Y
Y
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D006801:Humans; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D016017:Odds Ratio
D000889:Anti-Arrhythmia Agents
Antiarythmiques de classe I et prévention de la mort subite après infarctus du myocarde.